Shionogi & Co. agreed to acquire global rights to the FDA‑approved amyotrophic lateral sclerosis therapy edaravone in a $2.5 billion deal with Tanabe Pharma Corp. The transaction gives Shionogi control of both oral and IV formulations marketed in the U.S. as Radicava ORS and Radicava I.V. Under the terms, Tanabe will form a new entity that houses the edaravone products; Shionogi’s purchase secures an immediately revenue‑generating asset and expands its rare‑disease portfolio. The move represents a near‑term commercial acquisition rather than an R&D play, supporting Shionogi’s revenue diversification strategy. Market observers will track how Shionogi integrates the product into global commercialization and whether the deal presages further buyouts of approved, smaller‑market neurotherapeutics.